Form 10-K Taysha Gene Therapies, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Taysha Gene Therapies (TSHA) PT Lowered to $31 at Jefferies
April 1, 2022 8:46 AM EDTJefferies analyst Eun Yang lowered the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $31.00 (from $41.00) while maintaining a Buy rating.
The analyst commented, "Prioritization of several key pipeline programs is positive (vs prior >20 gene therapy programs in development),... More
Taysha Gene Therapies (TSHA) PT Lowered to $37 at Oppenheimer
April 1, 2022 8:18 AM EDTOppenheimer analyst Kevin DeGeeter lowered the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $37.00 (from $45.00) while maintaining a Outperform rating.
The analyst commented, "TSHA disclosed restructuring to focus on giant axonal neuropathy (GAN) and Rett syndrome, confirming suggestive comments at our 3/15 conference (note). Restructuring includes:... More
